A Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6799477 Following Oral Administration of Single Ascending Doses in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2015
At a glance
- Drugs RO 6799477 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Roche
- 22 Oct 2013 New trial record
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.